Phase II study of nimotuzumab combination with paclitaxel and cisplatin as the first-line treatment in patients with local advanced or metastatic esophageal squamous cell cancer (ESCC): An interim analysis

被引：0
|
作者：
Zhang, Xiaodong
Lu, Ming
Gong, Jifang
Gao, Jing
Wang, Xicheng
Zhang, Xiaotian
Li, Jie
Li, Yan
Li, Jian
Zhou, Jun
Lu, Zhihao
Shen, Lin
机构：
[1] Peking Univ, Sch Oncol, Dept Gastrointestinal Oncol, Beijing 100871, Peoples R China
[2] Beijing Canc Hosp & Inst, Beijing, Peoples R China
[3] Peking Univ, Canc Hosp, Beijing 100871, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14604
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study
    Su Jin Lee
    Sungmin Kim
    Moonjin Kim
    Jeeyun Lee
    Yeon Hee Park
    Young-Hyuck Im
    Se Hoon Park
    BMC Cancer, 15
  • [2] Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study
    Lee, Su Jin
    Kim, Sungmin
    Kim, Moonjin
    Lee, Jeeyun
    Park, Yeon Hee
    Im, Young-Hyuck
    Park, Se Hoon
    BMC CANCER, 2015, 15
  • [3] Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trial
    Lu, Ming
    Wang, Xicheng
    Shen, Lin
    Jia, Jun
    Gong, Jifang
    Li, Jie
    Li, Jian
    Li, Yan
    Zhang, Xiaotian
    Lu, Zhihao
    Zhou, Jun
    Zhang, Xiaodong
    CANCER SCIENCE, 2016, 107 (04) : 486 - 490
  • [4] Phase II trial of irinotecan and cisplatin combination as first-line chemotherapy in patients with advanced esophageal squamous-cell carcinoma: An interim report
    Zhang, X.
    Shen, L.
    Li, J.
    Li, Y.
    Zhou, J.
    Lu, Z.
    Lu, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [5] A multicenter phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer
    Kim, J.
    Song, H.
    Do, Y.
    Kim, M.
    Lee, K.
    Bae, S.
    Ryoo, H.
    Park, K.
    Baek, J.
    Lee, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [6] Interim analysis of a phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer
    Luck, HJ
    Thomssen, C
    duBois, A
    Lisboa, BW
    Untch, M
    Kuhnle, H
    Konecny, G
    Janicke, F
    Meerpohl, HG
    Lindner, C
    Hecker, D
    Diergarten, K
    SEMINARS IN ONCOLOGY, 1996, 23 (01) : 33 - 36
  • [7] Cost-Effectiveness Analysis of Toripalimab Plus Paclitaxel and Cisplatin as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma
    Fang, Rui
    Wang, Suiqiong
    Liu, Yongqian
    Xu, Jun
    ADVANCES IN THERAPY, 2023, 40 (03) : 1019 - 1030
  • [8] Cost-Effectiveness Analysis of Toripalimab Plus Paclitaxel and Cisplatin as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma
    Rui Fang
    Suiqiong Wang
    Yongqian Liu
    Jun Xu
    Advances in Therapy, 2023, 40 : 1019 - 1030
  • [9] Nimotuzumab plus paclitaxel and cisplatin as first-line treatment for esophageal squamous cell cancer: A single center prospective clinical trial.
    Zhang, Xiaodong
    Lu, Ming
    Wang, Xicheng
    Li, Jie
    Li, Yan
    Li, Jian
    Zhang, Xiaotian
    Gao, Jing
    Zhou, Jun
    Lu, Zhihao
    Gong, Jifang
    Jia, Jun
    Cui, Yan
    Yu, Jing
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] HEALTH OUTCOME IN PATIENTS WITH ADVANCED OR METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA TREATED WITH FIRST-LINE SINTILIMAB PLUS CISPLATIN AND PACLITAXEL VERSUS CISPLATIN AND PACLITAXEL
    Sun, L.
    VALUE IN HEALTH, 2022, 25 (12) : S53 - S53
12345